アトラグループ announced a capital and business alliance under which it will subscribe to a third-party allotment by REMED JAPAN and acquire 35% of voting rights. Going forward, it aims to raise its voting rights to more than 50% by exercising its right to acquire an additional stake.
アトラグループ is scheduled to acquire 156,154 common shares of REMED JAPAN through a third-party allotment, for an acquisition price of ¥78,077,000. Its voting rights ownership ratio after the acquisition is expected to be 35.0%. In addition, REMED JAPAN is expected to become an equity-method affiliate of アトラグループ, with 2 of the 4 directors to be dispatched by アトラグループ. In the future, アトラグループ may exercise a call option to additionally acquire shares of REMED JAPAN held by REMED equivalent to 16% of voting rights, which is expected to raise its voting rights ratio to 51%.
As background, アトラグループ signed a memorandum of understanding with REMED in April 2026 and has been considering collaboration between medical devices and the network of clinics that have introduced A-COMS. The establishment of a capital relationship is intended to promote sales expansion in the Japanese market. REMED's devices are expected to be supplied and rolled out through a network centered on acupuncture and osteopathic clinics.